| Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of … M Tanashat, A Manasrah, M Abouzid European Journal of Clinical Pharmacology, 1-13, 2024 | 2 | 2024 |
| Author’s reply to the letter to the editor:“Effects of dapagliflozin and empagliflozin on 6‑min walk distance in heart failure with preserved and reduced ejection fraction: A … M Tanashat, A Manasrah, M Abouzid European Journal of Clinical Pharmacology 80 (11), 1843-1844, 2024 | | 2024 |
| C-63| Effects of Dapagliflozin and Empagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved and Reduced Ejection Fraction: A Systematic Review and Meta-Analysis … MM Turkmani, M Tanashat, A Manasrah, D Salam, M Abouzid Journal of the Society for Cardiovascular Angiography & Interventions 3 (5), 2024 | | 2024 |
| Outcomes of HLA-DPB1 Mismatch in Patients Receiving Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis V Gannamani, A Baranwal, AM Manasrah, M Hefazi, A Mangaonkar, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Severe Late Agranulocytosis Post-Allogeneic Stem Cell Transplant during Tacrolimus Taper AM Manasrah, WJ Hogan, HB Alkhateeb Transplantation and Cellular Therapy 30 (2), S268, 2024 | | 2024 |
| Chronic Graft-Versus-Host Disease Leptomeningitis Following Allogeneic Stem Cell Transplant. AM Manasrah, WJ Hogan, HB Alkhateeb Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| EPH133 Real-World Effectiveness of Osimertinib in Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation: Systematic Review and Meta-Analysis A Almutairi, N Alkhatib, M Maghaireh, S Halloush, O Rashdan, ... Value in Health 26 (6), S188, 2023 | | 2023 |
| Economic evaluation of crizotinib, alectinib, ceritinib, and brigatininb in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) as second-line treatment. NS Alkhatib, B Choi, H Halawah, M Calamia, D Gulick, AM Manasrah, ... Journal of Clinical Oncology 39 (15_suppl), e21104-e21104, 2021 | | 2021 |
| Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naïve anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). B Choi, NS Alkhatib, H Halawah, M Calamia, D Gulick, AM Manasrah, ... Journal of Clinical Oncology 39 (15_suppl), e21102-e21102, 2021 | | 2021 |
